Overview of pulmonary function tests

Pulmonary function testing is an essential tool for the pulmonologist.
Insight into the underlying pulmonary pathophysiology can be gained by comparison with normal values (based on age, height, race and sex) and with the same patient’s previous values.
The percentage of the predicted normal value is used to grade the severity of abnormalities.

Click to enlarge the image


PFTs allow an objective assessment of lung function. This enables a more precise definition of respiratory mechanics, lung parenchymal function, gas exchange and cardiopulmonary interactions. These results are reproducible and quantitative, allowing monitoring over time. Respiratory symptoms alone tend to correlate poorly with the severity and progression of disease, so objective measurement is important.

PFTs are used to screen for obstructive and restrictive diseases, assess patients before surgery, document the progression of lung disease, document the effectiveness of a therapeutic intervention and monitor the pulmonary toxicity of drugs. Contraindications to PFTs include recent eye surgery, thoracic, abdominal and cerebral aneurysms, active haemoptysis, pneumothorax and unstable angina/myocardial infarction within the past month.

Spirometry measures the volume of air a patient exhales or inhales as a function of time. The forced vital capacity (FVC) manoeuvre requires the patient to forcefully expel air from the point of maximum inspiration (total lung capacity [TLC]) to the point of maximum expiration (residual volume [RV]).

The forced expiratory volume in the first second of the FVC manoeuvre (FEV1) and the FEV1/FVC ratio are key to determining whether obstruction is present. A graphical representation of inhalation and exhalation plotted as a function of volume (a flow-volume loop) allows subtle airflow abnormalities to be identified. FEV1/FVC (usually reported as a percentage) indicates what percentage of the total FVC was expelled from the lungs during the first second of forced expiration.


Total lung capacity is more difficult to measure. Although spirometry can measure inhaled and exhaled volumes, it cannot determine the total amount of air in the lungs at full inspiration (TLC), the amount of air remaining in the lungs at the end of a quiet (tidal) expiration (functional residual capacity), or the amount of air remaining after maximum expiration (RV). These volumes can be determined by inert gas dilution and body plethysmography, which uses Boyle’s law to determine lung volumes from changes in pressure and volume during breathing in a closed box.

Functional residual capacity (FRC)

- is the volume of air in the lungs at the end of tidal expiration.

FRC helps maintain a steady arterial oxygen tension, helps prevent atelectasis and helps minimise the work of breathing. Total lung capacity (TLC) equals the sum of functional residual capacity (FRC) and inspiratory capacity (IC), or the sum of residual volume (RV) and vital capacity (VC). A total lung capacity of less than 80% of predicted is generally considered consistent with restrictive lung disease.


Another PFT manoeuvre is diffusing capacity (DLCO), which attempts to define the diffusion properties of the membrane through which oxygen and carbon dioxide diffuse. Diffusing capacity depends on the rate at which gas enters the blood divided by its driving pressure and assesses the lungs’ ability to transport inhaled gas from the alveoli to the pulmonary capillaries. This transport depends on the thickness of the alveolar-capillary membrane, haemoglobin concentration and pulmonary blood flow. Diffusing capacity is generally assessed using a single-breath carbon monoxide (CO) test. CO is used because of its high affinity for haemoglobin, which is approximately 200 times greater than that of oxygen. Under normal conditions, there is a low concentration in the blood and a pulmonary concentration. A reduction in DLCO occurs in structural lung disease, pulmonary hypertension, congestive heart failure, a reduction in effective alveolar units (e.g. lung resection, emphysema) and anaemia. A high DLCO is most commonly associated with large lung volumes, obesity and asthma, although it can also be seen in alveolar haemorrhage or when the patient performs a Valsalva manoeuvre during testing.

 

The 6-minute walk test has been used to assess the functional status of patients with a wide range of pulmonary diseases, including pulmonary hypertension, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis.

This test can predict mortality in several end-stage lung diseases and has largely replaced cardiopulmonary exercise testing in the assessment of lung disease. It is much easier to perform, with lower associated costs and good reproducibility.

 

Impaired diffusing capacity (DLCO)

DLCO is the most sensitive parameter for detecting the loss of functional alveolar surface area and measures the forces involved in molecular movement along its concentration gradient from the alveolar surface to the haemoglobin molecule. Haemoglobin concentration is a very important measurement when interpreting a reduction in DLCO. Because the haemoglobin present in the alveolar capillaries serves as a sink for carbon monoxide, DLCO may be reduced when the patient is anaemic, and haematological abnormalities are fairly common in patients with sarcoidosis, with anaemia due to non-caseating granulomas and an absence of iron stores in the bone marrow. A reduction in DLCO is highly indicative of gas-exchange abnormalities during exercise in patients with sarcoidosis, and DLCO and arterial desaturation during physical exertion are the strongest functional parameters correlating with the extent and severity of sarcoidosis, as assessed either by pathological findings or high-resolution CT. This reduction also correlates with the loss of diffusing capacity of the alveolar membrane rather than with changes in pulmonary capillary blood volume.

Pulmonary hypertension (PH) is seen in sarcoidosis (5-15% of patients), but is present in more than 50% of patients with longstanding dyspnoea, and there is a strong inverse correlation between mean pulmonary artery pressure and DLCO. PH complicating sarcoidosis is associated with reduced exercise capacity. PH is more often associated with advanced sarcoidosis and reduced lung volume, but severe PH is observed without significant restriction. Reduced DLCO and resting hypoxaemia or desaturation during exercise correlate with the presence of PH in sarcoidosis.

Additional information

Pulmonary function tests measure how well the lungs move air and transfer oxygen. Spirometry, lung volumes and diffusion testing may be used to assess breathing and to follow changes over time. Results must be interpreted with symptoms, examination and imaging; a single result does not diagnose sarcoidosis. Follow the testing instructions and discuss any change with your clinician.

Rating: 0 stars
0 votes